TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20815183

Group type: EXPERIMENTAL
Intervention: Modafinil (2 x 100 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 22
Study: 18279531

Group type: EXPERIMENTAL
Intervention: Current evidence‐based strategies for management and prevention of CDAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 16192544

Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (ICB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Humeral block (HB)
Number of subjects: 120
Study: 11956450

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 9503219

Group type: EXPERIMENTAL
Intervention: 10% low‐molecular weight hydroxyethylstarch (HES) for 5 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: 20% human albumin (HA) for 5 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 10% low‐molecular weight hydroxyethylstarch (HES) for 5 days (HES‐sepsis)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Volume replacement using albumin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Volume therapy with 10% HES for 5 days
Number of subjects: 300
Study: 8564565

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ATRA + chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 2796891

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (COHb level of about 17%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 0
Study: 81323

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 87

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 87
Study: 31322552

Group type: EXPERIMENTAL
Intervention: Group A (brachial plexus anesthesia on blocked side)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group C (RIC conducted before regional anesthesia)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group B (brachial plexus anesthesia on non-blocked side)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 45
Study: 28325638

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 3037

Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 3037
Study: 25691510

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (PI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (P-PCI)
Number of subjects: 0
Study: 23447846

Group type: EXPERIMENTAL
Intervention: Ad libitum fluid replacement
Number of subjects: 57

Group type: COMPARATOR
Intervention: Restricted fluid replacement
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fluid intake of 300 ml/h
Number of subjects: 57
Study: 21835316

Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Initial medical therapy with deferred revascularization
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Insulin sensitization
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin provision
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 2368
Study: 20183450

Group type: EXPERIMENTAL
Intervention: Mean cumulative function (MCF) approach for analyzing adverse events data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crude incidence rates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure-adjusted incidence rates
Number of subjects: 0
Study: 17124897

Group type: EXPERIMENTAL
Intervention: WaveLight Allegretto Wavefront-Optimized system
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alcon CustomCornea system
Number of subjects: 14
Study: 15005471

Group type: EXPERIMENTAL
Intervention: School-based oral health education programme
Number of subjects: 803
Study: 11439393

Group type: EXPERIMENTAL
Intervention: Tractor work assignment
Number of subjects: 1138

Group type: COMPARATOR
Intervention: NAGCAT recommendations
Number of subjects: 1138
Study: 9175404

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study: 1606095

Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: No premedication (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall premedicated patients
Number of subjects: 80
Study: 3914860

Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 30823411

Group type: EXPERIMENTAL
Intervention: CGMP‐AA and usual dietary Phe (R1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CGMP‐AA − Phe content of CGMP‐AA from usual diet (R2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: L‐AA and usual dietary Phe (R3)
Number of subjects: 19
Study: 28434271

Group type: EXPERIMENTAL
Intervention: Oxygen washout procedure after intubation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no oxygen washout)
Number of subjects: 24
Study: 25844821

Group type: EXPERIMENTAL
Intervention: Lansoprazole (treated poor metabolizers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (treated children)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole (treated extensive metabolizers)
Number of subjects: 0
Study: 23474701

Group type: EXPERIMENTAL
Intervention: Subliminal activation of implicit unfairness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 21851299

Group type: EXPERIMENTAL
Intervention: Infected with 1.5 x 10^9 cfu M. haemolytica in 5 mL sterile nutrient broth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group inoculated with 5 mL sterile nutrient broth
Number of subjects: 20
Study: 17853034

Group type: EXPERIMENTAL
Intervention: 3D stereologic technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no LUTS)
Number of subjects: 15
Study: 16965682

Group type: EXPERIMENTAL
Intervention: Docetaxel (made in Beijing) 75 mg/m² plus cisplatin 70 mg/m²
Number of subjects: 77

Group type: COMPARATOR
Intervention: Docetaxel (made in Jiangsu) 75 mg/m² plus cisplatin 70 mg/m²
Number of subjects: 77
Study: 12767735

Group type: EXPERIMENTAL
Intervention: Folate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard haemodialysis treatment
Number of subjects: 0
Study: 10867427

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (EC40) after dental treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Full dental treatment only
Number of subjects: 23
Study: 8637402

Group type: EXPERIMENTAL
Intervention: Melanotan-II (MT-II) at doses of 0.01 mg/kg, escalated to 0.025 mg/kg and 0.03 mg/kg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 3
Study: 1595533

Group type: EXPERIMENTAL
Intervention: Adenosine (n = 14)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Verapamil (n = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 32
Study: 3927332

Group type: EXPERIMENTAL
Intervention: Pizotifene (4 mg daily for 3 days orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naloxone-HCI (0.8 mg intravenously)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No drug treatment (control group)
Number of subjects: 18
Study: 3771853

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 31823403

Group type: EXPERIMENTAL
Intervention: Personalized model (model-P)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Baseline model (model-B)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Clinical experts
Number of subjects: 266
Study: 29871618

Group type: EXPERIMENTAL
Intervention: Health check intervention
Number of subjects: 98
Study: 28794206

Group type: COMPARATOR
Intervention: Iron and folic acid capsule (IFA) daily from ≤20 wk gestation until delivery, followed by placebo daily from delivery to 6 mo postpartum
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) daily from ≤20 wk gestation to 6 mo postpartum
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) capsule daily from ≤20 wk gestation to 6 mo postpartum
Number of subjects: 647
Study: 26211828

Group type: EXPERIMENTAL
Intervention: Adenosine-guided ablation
Number of subjects: 534

Group type: COMPARATOR
Intervention: No further ablation (Control)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Patients without dormant pulmonary vein conduction
Number of subjects: 534
Study: 24072231

Group type: EXPERIMENTAL
Intervention: Paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy
Number of subjects: 32
Study: 20495502

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin of < 9.0 g/dL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin of ≥ 13.0 g/dL)
Number of subjects: 60
Study: 19118735

Group type: EXPERIMENTAL
Intervention: Surgical bypass for infrainguinal disease (specific intervention details not provided)
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Risk stratification model based on predictors (dialysis, tissue loss, age >or=75, hematocrit <or=30, advanced CAD)
Number of subjects: 2110
Study: 17162997

Group type: EXPERIMENTAL
Intervention: Sleep session
Number of subjects: 13

Group type: COMPARATOR
Intervention: Daytime wake session
Number of subjects: 13
Study: 14602771

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Bezafibrate (800 mg/d)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU/d) in simvastatin-treated patients
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU/d) in bezafibrate-treated patients
Number of subjects: 67
Study: 10927732

Group type: EXPERIMENTAL
Intervention: Nurse-led anticoagulation clinic with near-patient testing and computerized decision support software
Number of subjects: 367

Group type: COMPARATOR
Intervention: Routine hospital management (control)
Number of subjects: 367
Study: 8881624

Group type: EXPERIMENTAL
Intervention: Eltanolone 0.75 mg kg‐1
Number of subjects: 76

Group type: COMPARATOR
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 76

Group type: COMPARATOR
Intervention: Thiopentone 4 mg kg‐1
Number of subjects: 76
Study: 15278580

Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg(‐1) vecuronium (low dose group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.20 mg.kg(‐1) vecuronium (high dose group)
Number of subjects: 18
Study: 6375469

Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg t.i.d.)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg t.i.d.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flunarizine and Pentoxifylline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo, Flunarizine, Pentoxifylline
Number of subjects: 31
Study: 30791950

Group type: EXPERIMENTAL
Intervention: Scenarios labeled as 'cancer'
Number of subjects: 167

Group type: COMPARATOR
Intervention: Scenarios labeled as 'serious illness' (Control)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Scenarios labeled as 'cancer' (more serious scenarios)
Number of subjects: 167
Study: 28212390

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation (2 g/d EPA and 1 g/d DHA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Olive Oil (OO) control (3 g/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both FO and OO groups pooled
Number of subjects: 26
Study: 25443593

Group type: EXPERIMENTAL
Intervention: SHARP program (Staying Healthy‐Asthma Responsible and Prepared™)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 205
Study: 23680248

Group type: EXPERIMENTAL
Intervention: High SES group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 100
Study: 21375784

Group type: EXPERIMENTAL
Intervention: Lung cancer screening (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 0
Study: 19415504

Group type: EXPERIMENTAL
Intervention: Survivorship care plans (SCP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supportive care and psychosocial elements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Discussion and preparation of SCP
Number of subjects: 20
Study: 17979579

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a mean dose of 14.22 mg/day, n = 63
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (PL), n = 51
Number of subjects: 114
Study: 15006914

Group type: EXPERIMENTAL
Intervention: Yeast-based tablet with selenium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yeast-based tablet without selenium
Number of subjects: 0
Study: 11431613

Group type: EXPERIMENTAL
Intervention: 1-hour postprandial plasma glucose screening test
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1-hour 50 gm plasma glucose test screening test
Number of subjects: 100
Study: 9537619

Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing 154 microg phylloquinone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline solution containing 154 microg phylloquinone
Number of subjects: 12
Study: 8124970

Group type: EXPERIMENTAL
Intervention: Selective decontamination therapy (oral and enteral selective decontamination with amphotericin B, polymyxin E, and tobramycin)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (oral paste and enteral solution)
Number of subjects: 72
Study: 2510285

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rioprostil 150 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rioprostil 25 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rioprostil 50 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rioprostil 200 micrograms
Number of subjects: 33
Study: 350904

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% astringent solution mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 31530655

Group type: EXPERIMENTAL
Intervention: Neuroform stent (NEU)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Enterprise stent (EP)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Low-profile Visualized Intraluminal Support stent (LVIS)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Intra-procedural complications
Number of subjects: 659

Group type: COMPARATOR
Intervention: Post-procedural complications
Number of subjects: 659

Group type: COMPARATOR
Intervention: Braided-stents vs laser-cut stents
Number of subjects: 659
Study: 31149935

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 617
Study: 28116974

Group type: EXPERIMENTAL
Intervention: Original indications (19 drugs, 31 studies)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Supplemental indications (18 drugs, 33 studies)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: All indications
Number of subjects: 299
Study: 25561293

Group type: EXPERIMENTAL
Intervention: 25‐Hydroxyvitamin‐D (25‐VD3) levels in CRSwNP patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 25‐Hydroxyvitamin‐D (25‐VD3) levels in CRSsNP patients
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (noninflammatory pathology)
Number of subjects: 57
Study: 22820813

Group type: EXPERIMENTAL
Intervention: Educational cartoon story
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reward calendar
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parent information leaflet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (picture to color)
Number of subjects: 120
Study: 21114527

Group type: EXPERIMENTAL
Intervention: Highly hydrolysed formula
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cow's milk-based formula
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hydrolysed formula
Number of subjects: 240
Study: 19164422

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol vs. Metoprolol tartrate
Number of subjects: 0
Study: 16704735

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) - 6-dose course (20/120 mg tablets) over three days
Number of subjects: 119

Group type: COMPARATOR
Intervention: Artesunate plus amodiaquine (AAMQ) - 3-day course (4 mg/kg artesunate and 10 mg/kg amodiaquine)
Number of subjects: 119
Study: 14992881

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (80 mg/kg ideal weight preoperatively and 8 mg/kg ideal weight IV per hour for 48 hours)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (dextrose 5% water)
Number of subjects: 202
Study: 11381810

Group type: EXPERIMENTAL
Intervention: Cuff pressure equal to or less than 42 mmHg (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cuff pressure higher than 42 mmHg (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cuff pressure
Number of subjects: 40
Study: 9154884

Group type: EXPERIMENTAL
Intervention: Cefuroxime (two 1,500 mg doses 12 hours apart after intubation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no cefuroxime, 17 patients received prophylactic antibiotics)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (patients receiving prior antibiotics)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (patients not receiving prior antibiotics)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefuroxime and/or prior antibiotics in control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with pneumonia (both groups)
Number of subjects: 100
Study: 7835794

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel (24-hr infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study: 3322670

Group type: EXPERIMENTAL
Intervention: 1‐propranolol (Obsidan)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29944874

Group type: EXPERIMENTAL
Intervention: C-arm-guided reduction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (palpation, auditory cues, visualization of symmetry)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (C-arm and control)
Number of subjects: 20
Study: 28643733

Group type: EXPERIMENTAL
Intervention: Gem/Cis (Cisplatin 40 mg/m2 on day 1 and day 8 combined with Gemcitabine 1000 mg/m2 on day 1 and day 8)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Gem/Carb (Carboplatin AUC 5 on day 1 combined with Gemcitabine 1000 mg/m2 on day 1 and day 8)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study: 25909369

Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglicate emulsion
Number of subjects: 177

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 177
Study: 22983820

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) added to Standard Care (SC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 79
Study: 20370452

Group type: EXPERIMENTAL
Intervention: Mupirocin applied once weekly (Group I)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mupirocin applied three times weekly (Group II)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prior to mupirocin treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall mupirocin application
Number of subjects: 33
Study: 18349395

Group type: EXPERIMENTAL
Intervention: EGF vaccinations
Number of subjects: 80

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 80
Study: 17163233

Group type: COMPARATOR
Intervention: 7.5 mg of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg of 0.66% hyperbaric ropivacaine (Group R)
Number of subjects: 40
Study: 15071253

Group type: EXPERIMENTAL
Intervention: Atrial therapies ON
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atrial therapies OFF
Number of subjects: 0
Study: 10749277

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 96
Study: 8933485

Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training at 80% of one-repetition maximum, 8 repetitions per set, 3 sets per session, twice weekly for 12 weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy elderly nontraining subjects).
Number of subjects: 24
Study: 7921445

Group type: EXPERIMENTAL
Intervention: KS1/4-methotrexate (KS1/4-MTX) immunoconjugate, maximal tolerated dose of 1,750 mg/M2, cumulative dose of MTX of 40 mg/M2
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: KS1/4-methotrexate (KS1/4-MTX) immunoconjugate
Number of subjects: 11
Study: 3135144

Group type: EXPERIMENTAL
Intervention: 300 mg oral lithium carbonate load (8.1 mmol of elemental lithium)
Number of subjects: 0